A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options-Reference-Cited by-同舟云学术

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options

Published:2022-10-25 Issue: Volume: Page:570-581
ISSN:2692-3114
Container-title:Exploration of Targeted Anti-tumor Therapy
language:
Short-container-title:

Author:

Criscuolo Daniela¹^ORCID,Morra Francesco²^ORCID,Celetti Angela²^ORCID

Affiliation:

1. Institute for the Experimental Endocrinology and Oncology, Research National Council, CNR, 80131 Naples, Italy; Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy

2. Institute for the Experimental Endocrinology and Oncology, Research National Council, CNR, 80131 Naples, Italy; Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy

Abstract

Solute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of tumor-associated ferroptosis. Accumulating evidence has demonstrated that xCT overexpression, resulting from different oncogenic and tumor suppressor signaling, promotes tumor progression and multidrug resistance partially via suppressing ferroptosis. In addition, recent studies have highlighted the role of xCT in regulating the metabolic flexibility in cancer cells. In this review, the xCT activities in intracellular redox balance and in ferroptotic cell death have been summarized. Moreover, the role of xCT in promoting tumor development, drug resistance, and nutrient dependency in cancer cells has been explored. Finally, different therapeutic strategies, xCT-based, for anti-cancer treatments have been discussed.

Publisher

Open Exploration Publishing

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference86 articles.

1. Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018;38:12.

2. Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers (Basel). 2019;11:678.

3. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.

4. Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181–92.

5. Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599–620.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel SLC3A2-targeting antibody-drug conjugate exerts potent antitumor efficacy in head and neck squamous cell cancer;Translational Oncology;2024-07

2. Formyl-Peptide Receptor 2 Signaling Modulates SLC7A11/xCT Expression and Activity in Tumor Cells;Antioxidants;2024-04-30

3. Neutrophil-Derived IL-6 Potentially Drives Ferroptosis Resistance in B Cells in Lupus Kidney;Mediators of Inflammation;2023-05-27